SCHEMBL2401668

SCHEMBL2401668

CC(=O)/C=C/c1ccc(C(F)(F)F)nc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.50
GLA P06280 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
IAPP P10997 1/20 0.44
PTGS1 P23219 1/20 0.44
FDPS P14324 1/20 0.42
APP P05067 4/20 0.42
TRPV4 Q9HBA0 1/20 0.42
P4HTM Q9NXG6 1/20 0.41
CYP1A2 P05177 1/20 0.41
HDAC3 O15379 1/20 0.38
ADAM17 P78536 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
CYP1A1 P04798 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2401676 1.00 TRPV1 (0.50) TRPV1GLATDP1IAPPPTGS1
SCHEMBL454424 0.85 P4HTM (0.58) TRPV1GLATDP1APPTRPV4
SCHEMBL30025274 0.85 P4HTM (0.58) TRPV1GLATDP1APPTRPV4
SCHEMBL3662968 0.85 P4HTM (0.58) TRPV1GLATDP1APPTRPV4
SCHEMBL454425 0.85 P4HTM (0.58) TRPV1GLATDP1APPTRPV4
SCHEMBL1124343 0.84 TRPV1 (0.50) TRPV1APPTRPV4P4HTMCYP1A2
SCHEMBL1124342 0.84 TRPV1 (0.50) TRPV1APPTRPV4P4HTMCYP1A2
SCHEMBL1124462 0.84 TRPV1 (0.50) TRPV1APPTRPV4P4HTMCYP1A2
Hydrochloric Acid SCHEMBL27833446 0.84 P4HTM (0.57) TRPV1GLATDP1APPTRPV4
SCHEMBL1124460 0.84 TRPV1 (0.50) TRPV1APPTRPV4P4HTMCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415380-B2 Pyridine and pyrimidine derivatives as MGLUR2 antagonists HOFFMANN-LA ROCHE INC. (US) 2013-04-09 US disclosed
US-20110263615-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS GATTI MCARTHUR SILVIA 2011-10-27 US disclosed
US-8012986-B2 Pyridine and pyrimidine derivatives as MGLUR2 antagonists HOFFMANN-LA ROCHE INC. (US) 2011-09-06 US disclosed
EP-2142527-B1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-12-29 EP disclosed
US-20080280924-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS HOFFMAN-LA ROCHE, INC. 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263615-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS GRM2, GRIN2B, GRM1 TRPV1 328/4885GLA 4802/4885TDP1 2184/4885
US-20080280924-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS GRM2, GRIN2B, GRM1 TRPV1 328/4885GLA 4802/4885TDP1 2184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.